Нефинансовые факторы эффективности фармацевтических компаний в России

Развитие фармацевтической отрасли неразрывно связано с разработками новых видов лекарственных препаратов, внедрением новых технологий, обеспечением научных исследований в биоинженерии и биотехнологии, что может быть обеспечено посредством непрерывного развития интеллектуального капитала. Интеллектуальный капитал — емкое и неоднозначно трактуемое понятие, при прочих равных, объясняемое  наличием профессиональных навыков и компетенций сотрудников, которые не могут быть отделены от них, а, следовательно, и отражены в отчетности. В течение длительного времени исследователи оценивали влияние интеллектуального капитала на эффективность деятельности и стоимость компаний в различных отраслях экономики. В данной статье предпринята попытка взглянуть на проблему шире путем добавления неотъемлемых для устойчивого развития и конкурентных преимуществ компании факторов: бизнес-модели и бизнес-стратегии к традиционным элементам интеллектуального капитала.

Цель работы заключается в оценке влияния бизнес-стратегии, бизнес-модели и компонентов интеллектуального капитала на эффективность деятельности компаний фармацевтического сектора в России. Объектом исследования является финансовая и нефинансовая отчетность российских фармацевтических компаний. Предмет — установление взаимосвязи между раскрытием информации об интеллектуальном капитале и финансовыми показателями с учетом бизнес-стратегии и бизнес-модели компании. Методологической базой является статистико-экономический метод, а именно, регрессия панельных данных с детерминированными (фиксированными) эффектами. Результаты показали, что большая часть крупных компаний фармацевтического сектора придерживаются бизнес-стратегии «анализаторов» и выбирают бизнес-модель производителей собственных лекарственных препаратов. Полученные выводы свидетельствуют об отсутствии связи бизнес-стратегии и бизнес-модели компании с эффективностью деятельности фармацевтических компаний. Установлены элементы интеллектуального капитала, которые обеспечивают конкурентные преимущества компании в фармацевтической отрасли.

1. Alcaniz, L., Gomez-Bezares, F., Roslender, R. (2011). Theoretical perspectives on intellectual capital: A backward look and a proposal for going forward. Accounting Forum, 35(2), 104-117. DOI: 10.1016/j.accfor.2011.03.004

2. Ali, M.A., Hussin, N., Haddad, H., Al-Araj, R., Abed, I.A. (2021). A multidimensional view of intellectual capital: The impact on innovation performance. Journal of Open Innovation Technology, Market and Complexity, 7(4), 1-25. DOI: 10.3390/joitmc7040216

3. Andriessen, D., Stam, C. (2009). Intellectual Capital of the European Union 2008: Measuring the Lisbon Strategy for Growth and Jobs. Electronic Journal of Knowledge Management, 7(4), 489-500. Available at: View article (google.ru) (accessed 23.10.2022)

4. Baker, R.J. (2008). Mind over Matter: Why Intellectual Capital is the Chief Source of Wealth. New Jersey, John Wiley and Sons Publication. 340 p.

5. Bartholomew, D. (2008). Building on Knowledge: Developing Expertise, Creativity and Intellectual Capital in the Construction Professions. New York, Wiley Blackwell. 320 p.

6. Blaser, D.A., Lewtas, A.J., Ousterhout, M.M., Lee K.W., Hartman, S.J., Gagnon, J.M. (2010). How to define specialty Pharmaceuticals-A systematic review. American Journal of Pharmacy Benefits, 2 (6), 371-380. Available at: How to define specialty pharmaceuticals-A systematic review (researchgate.net) (accessed 23.10.2022)

7. Bontis, N. (2000). Intellectual Capital: An Exploratory Study That Develops Measures and Models. Journal of Management Decision, 36(2), 63-76. DOI:10.1108/00251749810204142

8. Bontis, N. (2001). Managing Organizational Knowledge by Diagnosing Intellectual Capital: Framing and Advancing the State of the Field. International Journal of Technology Management, 18, 433-463. DOI: 10.1504/IJTM.1999.002780

9. Bontis, N., Fitz‐Enz, J. (2002). Intellectual capital ROI: A casual map of human capital antecedents and consequents. Journal of Intellectual Capital, 3(3), 223‐247. DOI:10.1108/14691930210435589

10. Bozbura, F.T., Beskese, A., Kahraman, C. (2007). Prioritization of human capital measurement indicators using fuzzy AHP. Expert Systems with Applications, 32(4), 1100-1112. DOI: 10.1016/j.eswa.2006.02.006

11. Branstetter, L., Chatterjee, C., Higgins, M.J. (2022). Generic competition and the incentives for early-stage pharmaceutical innovation. Research Policy, 51(10). DOI:10.1016/j.respol.2022.104595

12. Buallay, A. (2017). The relationship between intellectual capital and firm performance. Corporate Governance and Organizational Behavior Review, 1(1), 32-41. DOI: 10.22495/cgobr_v1_i1_p4

13. Bukh, P.N., Larsen, H.T., Mouritsen, J. (2001). Constructing intellectual capital statements. Scandinavian Journal of Management, 17(1), 87-108. DOI:10.1016/S0956-5221(00)00034-8

14. Chen, C.-J., Huang, J.-W. (2009). Strategic human resource practices and innovation performance – the mediating role of knowledge management capacity. Journal of Business Research, 62(1), 104-114. DOI:10.1016/j.jbusres.2007.11.016

15. Chen, J., Zhu, Z., Xie, H.Y. (2004). Measuring intellectual capital: A new model and empirical study. Journal of intellectual capital, 5(1), 195‐212. DOI:10.1108/14691930410513003

16. Cole, A.L., Dusetzina, S. B. (2018). Generic Price Competition for Specialty Drugs: Too Little, Too Late? Health Affairs, 37(5), 738–742. DOI: 10.1377/hlthaff.2017.1684

17. Elda, R.P., Patrisia, D., Abror, A., Linda, M.R. (2021). The Impact of Intellectual Capital and Knowledge Management on Competitive Advantage. Advances in Economics, Business and Management Research, 179, 480-487. DOI:10.2991/aebmr.k.210616.075

18. Gautam, A., Pan, X. (2016). The changing model of big pharma: Impact of key trends. Drug Discovery Today, 21(3), 379–384. DOI:10.1016/j.drudis.2015.10.002

19. Gavious, I., Russ, M. (2009). The valuation implications of human capital in transactions on and outside the exchange. Advances in Accounting, 25(2), 165-173. DOI: 10.1016/j.adiac.2009.09.004

20. Ge, F., Xu, J. (2021). Does intellectual capital investment enhance firm performance? Evidence from pharmaceutical sector in China. Technology Analysis and Strategic Management, 33(9). 1006-1021. DOI:10.1080/09537325.2020.1862414

21. González-Rodrígueza, M.R., Jiménez-Caballeroa, J.L., Martín-Sampera, R.C., Köseoglub, M.A., Okumus, F. (2017). Revisiting the link between business strategy and performance: Evidence from hotels. International Journal of Hospitality Management, 72, 21-31. DOI:10.1016/j.ijhm.2017.11.008

22. Gupta, J., Rathore, P., Kashiramka, S. (2022). Impact of Intellectual Capital on the Financial Performance of Innovation-Driven Pharmaceutical Firms: Empirical Evidence from India. Journal of the Knowledge Economy, 6, 103-121. DOI:10.1007/s13132-022-00927-w

23. Hambrick, D.C. (1983). Some tests of the effectiveness and functional attributes of Miles and Snow’s strategic types. Academy of Management Journal, 26(1), 5-26

24. Hatch, N.W., Dyer, J.H. (2004). Human capital and learning as a source of sustainable competitive advantage. Strategic Management Journal, 25(12), 1155-1178. DOI:10.1002/smj.421

25. Hoque, Z. (2004). A contingency model of the association between strategy, environmental uncertainty and performance measurement: impact on organizational performance. International Business Review, 13(4), 485-502. DOI:10.1016/j.ibusrev.2004.04.003

26. Hosnavi, R., Ramezan, M. (2011). Intellectual Capital and Organizational Organic Structure How are these Concepts Related? Trends in Applied Sciences Research, 6(3), 256-268. DOI:10.3923/tasr.2011.256.268

27. Huang, H.C. (2011). Aligning intangible assets to innovation in biopharmaceutical industry. Expert Systems with Applications, 38(4), 3827-3834. DOI:10.1016/j.eswa.2010.09.043

28. Komnenic, B., Pokrajcic, D. (2012). Intellectual Capital and Corporate Performance of MNCs in Serbia. Journal of Intellectual Capital, 13(1), 106-119. DOI:10.1108/14691931211196231

29. Ku, M.S. (2015). Recent trends in specialty pharma business model. Journal of Food and Drug Analysis, 23(4), 595–608. DOI: 10.1016/j.jfda.2015.04.008

30. Lopo Martinez, A., Ferreira, B.A. (2019). Business strategy and tax aggressiveness in Brazil. Journal of Strategy and Management, 12(4), 522-535. DOI:10.1108/JSMA-03-2019-0040

31. Magerakis, E., Tzelepis, D. (2020). The impact of business strategy on corporate cash policy. Journal of Applied Accounting Research, 21(4), 677-699. DOI:10.1108/JAAR-05-2019-0077

32. Malhotra, Y. (2003). Measuring Knowledge Assets of a Nation: Knowledge Systems for Development Research. Ad Hoc Group of Experts Meeting Knowledge Systems for Development United Nations Headquarters. New York. 48 p.

33. Mehralian, G., Ghatari, A.R., Sadeh, M.R., Rasekh, H.R. (2012). Intellectual capital and corporate performance in Iranian pharmaceutical industry. Journal of Intellectual Capital, 13(1), 138-158. DOI: 10.1108/14691931211196259

34. Mehralian, G., Rajabzadeh, A., Reza Sadeh, M., Reza Rasekh, H. (2012). Intellectual capital and corporate performance in Iranian pharmaceutical industry. Journal of Intellectual Capital, 13(1), 138-158. DOI:10.1108/14691931211196259

35. Miles, R.E., Snow, C.C. (2003). Organizational Strategy, Structure, and Process. California, Stanford University Press. 274 p.

36. Miles, R.E., Snow, C.C., Meyer, A.D., Coleman, H.J. (1978). Organizational Strategy, Structure, and Process. The Academy of Management Review, 3(3), 546-562. DOI:10.5465/AMR.1978.4305755

37. Montequin, V., Ortega, F., Francisco, A. (2006). An Integrated Framework for Intellectual Capital Measurement and Knowledge Management Implementation in Small and Medium-Sized Enterprises. Journal of Information Science, 32(6), 525-538. DOI:10.1177/0165551506067127

38. Nadeem, M., Farooq, M.B., Ahmed, A. (2019). Does female representation on corporate boards improve intellectual capital efficiency? Journal of Intellectual Capital, 20(5), 680-700. DOI: 10.1108/JIC-01-2019-0007

39. Notta, O., Vlachvei, A. (2016). Competitive Strategies and Managers’ Perceptions in Greek Food Manufacturing Firms. In: Kavoura, A., Sakas, D.P., Tomaras, P. (Eds.). Strategic Innovative Marketing. Mykonos, Springer International Publishing, Cham. Pp. 245-251. DOI: 10.1007/978-3-319-33865-1_31

40. Parnell, J. A., Wright, P. (1993). Generic Strategy and Performance: An Empirical Test of the Miles and Snow Typology. British Journal of Management, 4.(1), 29-36. DOI:10.1111/j.1467-8551. 1993.tb00159.x

41. Pulic, A. (1998). Measuring the performance of intellectual potential in knowledge economy. 2nd McMaster Word Congress on Measuring and Managing Intellectual Capital by the Austrian Team for Intellectual Potential. Pp. 1-20.

42. Rafols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O’Hare, A., Perianes-Rodríguez, A., Nightingale, P. (2014). Big Pharma, little science? A bibliometric perspective on Big Pharma's R,D decline. Technological Forecasting and Social Change, 81, 22–38. DOI: 10.1016/j.techfore.2012.06.007

43. Ramezan, M. (2011). Intellectual capital and organizational organic structure in knowledge society: How are these concepts related? International Journal of Information Management, 31(1), 88-95. DOI: 10.1016/j.ijinfomgt.2010.10.004

44. Rep, A., Zager, K., Oliveira, C. (2019). The Role of Firm Characteristics in Voluntary Disclosure of IC Information and Its Importance for High-Tech Companies. Journal of Information and Organizational Sciences, 43(2), 185-209. DOI:10.31341/jios.43.2.4

45. Rudez, H.M., Mihalic, T. (2007). Intellectual capital in the hotel industry: A case study from Slovenia. International Journal of Hospitality Management, 26(1), 188–199. DOI:10.1016/j.ijhm.2005.11.002

46. Salvi, A., Vitolla, F., Giakoumelou, A., Raimo, N., Rubino, M. (2020). Intellectual capital disclosure in integrated reports: The effect on firm value. Technological Forecasting and Social Change, 160(2), 1-8. DOI: 10.1016/j.techfore.2020.120228

47. Sardo, F., Serrasqueiro, Z., Alves, H. (2018). On the Relationship Between Intellectual Capital and Financial Performance: A Panel Data Analysis on SME Hotels. International Journal of Hospitality Management, 75, 67-74. DOI: 10.1016/j.ijhm.2018.03.001

48. Treacy, M., Wiersema, F. (1995). The Discipline of Market Leaders: Choose Your Customers, Narrow Your Focus, Dominate Your Market. Boston, Addison-Wesley Publishing Company. 224 p.

49. Vishnu, S., Gupta, V. K. (2014). Intellectual capital and performance of pharmaceutical firms in India. Journal of Intellectual Capital, 15(1), 83-99. DOI: 10.1108/JIC-04-2013-0049

50. Wall, A. (2005). The Measurement and Management of Intellectual Capital in the Public Sector: Taking the Lead or Waiting for Direction? Public Management Review, 7(2), 289-303. DOI: 10.1080/14719030500091723

51. Xin, L., Chen, H., Zhang, R. (2020). The Impact of Intellectual Capital Efficiency on Corporate Sustainable Growth-Evidence from Smart Agriculture in China. Agriculture, 10(6), 1-15. DOI: 10.3390/agriculture10060199

52. Yang, C-C., Lin, C. (2009). Does intellectual capital mediate the relationship between HRM and organizational performance? Perspective of a healthcare industry in Taiwan. International Journal of Human Resource Management, 20(9), 1965-1984. DOI: 10.1080/09585190903142415

53. Yi, A., Howard, D. (2010). Intellectual capital disclosure in Chinese (mainland) companies. Journal of Intellectual Capital, 11(3), 326-347. DOI: 10.1108/14691931011064572

54. Žager, K., & Oliveira, C. (2019). The Role of Firm Characteristics in Voluntary Disclosure of IC Information and Its Importance for High-Tech Companies. Journal of Information and Organizational Sciences, 43(2), 185–209. https://doi.org/10.31341/jios.43.2.4